The intricate processes governing human health and disease are profoundly influenced by the immune system, a complex network designed to protect the body from threats. At its core, inflammation serves as a vital defensive response, signaling the presence of injury or infection and orchestrating the recruitment of immune cells and reparative mechanisms to neutralize dangers and mend damaged tissues. This acute inflammatory response is crucial for survival and healing. However, its prolonged activation, particularly as individuals advance in age, transitions from a beneficial protective measure into a detrimental force, underpinning a wide array of chronic illnesses that become increasingly prevalent later in life. This persistent, low-grade systemic inflammation, often termed "inflammaging," has been implicated in conditions ranging from cardiovascular disease and neurodegenerative disorders to metabolic syndromes and certain cancers.
For years, scientists have sought to unravel the molecular underpinnings of this age-related chronic inflammation. A significant breakthrough has recently emerged from collaborative research conducted by investigators at the Sanford Burnham Prebys Medical Discovery Institute, the Mayo Clinic, and their affiliated institutions. Their findings, meticulously detailed and published in the prestigious scientific journal Nature, illuminate a previously unrecognized and critical nexus between mitochondrial function, cellular metabolism, and the sustained inflammatory state characteristic of aging. Furthermore, the study demonstrated that experimentally disrupting a specific component of this newly identified pathway led to a tangible reduction in inflammation and fostered healthier aging outcomes in laboratory mice, opening promising new avenues for therapeutic intervention.
A central player in the narrative of age-related chronic inflammation is a peculiar class of cells known as senescent cells. Throughout life, the body’s tissues are constantly undergoing cycles of growth, repair, and regeneration, processes largely facilitated by the ability of many cells to divide. Yet, as the years accumulate, an increasing number of cells cease this proliferative activity, entering a state referred to as senescence. These "zombie-like" senescent cells are unique; while they no longer undergo division, they are far from inert. Instead, they remain metabolically active and exert significant influence on their surrounding microenvironment.
Dr. Peter Adams, a co-corresponding author of the study and the Jeanne and Gary Herberger Leadership Chair in Cancer Research at Sanford Burnham Prebys, as well as director and professor in the Cancer Genome and Epigenetics Program, emphasized this point. "Senescent cells are not completely inert," he stated. "They remain metabolically active and have an inflammatory program causing them to secrete inflammatory molecules." This inflammatory program, a hallmark of senescent cells, is formally known as the senescence-associated secretory phenotype, or SASP. The SASP involves the continuous release of a cocktail of pro-inflammatory cytokines, chemokines, growth factors, and proteases, which collectively fuel the widespread inflammation observed in aging tissues and contribute significantly to the pathogenesis of numerous age-related chronic diseases. Understanding the precise molecular machinery that drives SASP has been a key objective for researchers aiming to mitigate its detrimental effects.
The research team, spearheaded by the laboratory of senior and co-corresponding author Dr. João Passos, a professor of Physiology at Mayo Clinic, embarked on a mission to dissect the molecular processes that instigate and perpetuate SASP. Their overarching scientific objective was to determine whether these intricate pathways could be therapeutically modulated or even completely interrupted. What they uncovered was a fascinating convergence of at least two distinct biological pathways, both intricately linked to the mitochondria – the organelles often dubbed the "powerhouses of the cell."
Mitochondria are fundamental to cellular life, primarily responsible for generating the bulk of a cell’s energy currency, adenosine triphosphate (ATP), through cellular respiration. Beyond energy production, they participate in a myriad of other cellular processes, including metabolism, signaling, and programmed cell death. In the context of senescent cells, the researchers observed a marked divergence in mitochondrial behavior compared to their healthier, proliferating counterparts. Although senescent cells are non-dividing, they still possess a high metabolic demand, and their mitochondria exhibited a distinctive pattern of activity.
Specifically, the mitochondria within senescent cells were found to produce elevated quantities of acetyl-CoA, a crucial metabolic intermediate. Acetyl-CoA stands at a crossroads of cellular metabolism, playing roles in energy production, lipid synthesis, and the regulation of gene expression. Its interaction with histones proved to be particularly significant in this context. Histones are spool-like proteins around which DNA is tightly wound within the cell nucleus, forming a compact structure known as chromatin. The precise packaging of DNA around histones dictates which genes are accessible for transcription and, consequently, which proteins are produced. By chemically modifying these histones, acetyl-CoA can alter the structural integrity of chromatin, effectively loosening the DNA packaging. This epigenetic modification does not alter the underlying genetic code itself but rather changes how the genetic information is read and expressed. In senescent cells, this increased histone acetylation by elevated acetyl-CoA rendered specific genes, including those critical for the inflammatory SASP response, more accessible to the cellular machinery responsible for gene activation.
However, the scientists quickly realized that this metabolic alteration alone, while significant, was insufficient to fully explain the sustained release of inflammatory molecules by senescent cells. A second, complementary process was also indispensable for the full activation of the SASP.
Under conditions of cellular stress or damage, mitochondria themselves can become dysfunctional. When compromised, these organelles can inadvertently leak their own internal DNA and RNA into the cytoplasm, a compartment where these molecules are not typically found in abundance. The immune system, ever vigilant, interprets this misplaced mitochondrial genetic material as a potent danger signal. This intracellular immune response subsequently triggers the activation of specific transcription factors. These protein complexes are molecular switches that bind to DNA and regulate gene expression, essentially turning genes "on" or "off." In the context of senescent cells, these immune-activated transcription factors were then able to target and bind to the SASP genes that had already been rendered more accessible by the elevated levels of acetyl-CoA and the subsequent histone modifications.
In essence, the research team uncovered a remarkable convergence of two distinct yet synergistic mitochondrial processes. One pathway, driven by altered metabolism and increased acetyl-CoA production, epigenetically "prepares" the inflammatory SASP genes by making them physically accessible. The second pathway, initiated by the leakage of mitochondrial genetic material, provides the crucial immune signaling "trigger" necessary to activate these already exposed SASP genes. As Dr. Adams articulated, "It turns out that there is a convergence of at least two biological pathways related to mitochondria. One alters how DNA is stored to promote areas related to SASP, and the other boosts the expression of the exposed SASP genes." He further elaborated on their subsequent investigative steps: "After seeing how these two independent pathways intersect, we wanted to see if interrupting one could prevent their partnership in promoting SASP."
Armed with this dual-pathway understanding, the researchers proceeded to test a critical hypothesis: if these two pathways converge, could disrupting one of them effectively dismantle the entire inflammatory cascade? To explore this, they utilized a pharmacological agent known as CTPI-2. This compound functions by specifically blocking a transport protein responsible for carrying a precursor molecule essential for the production of acetyl-CoA. By inhibiting this transport, CTPI-2 effectively reduces the intracellular availability of components needed to synthesize acetyl-CoA.
When CTPI-2 was administered to laboratory mice, the results were compelling. The treatment led to a significant and widespread reduction in inflammation across various tissues throughout the animals’ bodies. Beyond merely dampening inflammatory markers, the intervention also yielded tangible improvements in tissue function and, remarkably, enhanced the overall healthspan of the aging mice. Importantly, the researchers observed that even with the administration of CTPI-2, the immune signals generated by leaking mitochondrial DNA and RNA were still present within the cells. However, by strategically weakening the metabolic signal involving acetyl-CoA – thereby making the SASP genes less accessible – the treatment effectively attenuated their inflammatory effects.
"Even though the immune signaling from leaky mitochondria was still present, disrupting the metabolic signal made SASP genes less accessible and produced functional benefits," Dr. Adams confirmed. This finding underscores the potential for a novel therapeutic strategy. He further suggested, "Using selective inhibitors such as CTPI-2 to reduce acetyl-CoA and, in turn, inflammation is a novel therapeutic strategy that should be explored."
This groundbreaking research carries profound implications for the future of aging research and the development of new treatments for age-related chronic diseases. It fundamentally shifts the paradigm by suggesting that targeting metabolic signals that influence DNA accessibility could represent an entirely new and powerful approach for mitigating age-associated inflammation and the functional decline that often accompanies it. Instead of merely addressing the downstream symptoms of chronic inflammation, this strategy offers a pathway to intervene at a more foundational cellular level, potentially altering the epigenetic landscape that drives the inflammatory response.
The insights gleaned from this study, spearheaded by first author Hélène Martini, PharmD, PhD, a postdoctoral researcher in the Passos lab at Mayo Clinic, and supported by various esteemed organizations including the National Institutes of Health, the Hevolution Foundation, and The Glenn Foundation for Medical Research, pave the way for a deeper understanding of the cellular and molecular mechanisms underlying aging. By unraveling how mitochondria orchestrate the activation of "zombie" cells’ inflammatory programs, scientists are now equipped with novel targets and strategies to potentially extend not just lifespan, but more importantly, healthspan – the period of life spent in good health and free from chronic disease. The prospect of leveraging metabolic control over gene accessibility presents a compelling frontier in the quest to combat the pervasive impact of inflammaging.
About the Author
